CONTEXT: Medication for the treatment of alcoholism is currently not particularly robust. Neuroimaging techniques might predict which medications could be useful in the treatment of alcohol dependence. OBJECTIVE: To explore the effect of naltrexone, ondansetron hydrochloride, or the combination of these medications on cue-induced craving and ventral striatum activation. DESIGN: Functional brain imaging was conducted during alcohol cue presentation. SETTING:Participants were recruited from the general community following media advertisement. Experimental procedures were performed in the magnetic resonance imaging suite of a major training hospital and medical research institute. PATIENTS: Ninety non-treatment-seeking alcohol-dependent (by DSM-IV criteria) and17 social drinking (< 14 drinks per week) paid volunteers recruited through advertisements at an academic center. INTERVENTIONS: A taste of alcohol and a series of alcohol-related pictures, neutral beverage pictures, and visual control images were provided to volunteers after 7 days of double-blind randomly assigned daily dosing with 50 mg of naltrexone (n = 23), 0.50 mg of ondansetron hydrochloride (n = 23), the combination of the 2 medications (n = 20), or matching placebos (n = 24). MAIN OUTCOME MEASURES: Difference in brain blood oxygen level-dependent magnetic resonance when viewing alcohol pictures vs neutral beverage pictures with a particular focus on ventral striatum activity comparison across medication groups. Self-ratings of alcohol craving. RESULTS: The combination treatment decreased craving for alcohol. Naltrexone with (P = .02) or without (P = .049) ondansetron decreased alcohol cue-induced activation of the ventral striatum. Ondansetron by itself was similar to naltrexone and the combination in the overall analysis but intermediate in a region-specific analysis. CONCLUSIONS: Consistent with animal data that suggest that both naltrexone and ondansetron reduce alcohol-stimulated dopamine output in the ventral striatum, the current study found evidence that these medications, alone or in combination, could decrease alcohol cue-induced activation of the ventral striatum, consistent with their putative treatment efficacy.
RCT Entities:
CONTEXT: Medication for the treatment of alcoholism is currently not particularly robust. Neuroimaging techniques might predict which medications could be useful in the treatment of alcohol dependence. OBJECTIVE: To explore the effect of naltrexone, ondansetron hydrochloride, or the combination of these medications on cue-induced craving and ventral striatum activation. DESIGN: Functional brain imaging was conducted during alcohol cue presentation. SETTING:Participants were recruited from the general community following media advertisement. Experimental procedures were performed in the magnetic resonance imaging suite of a major training hospital and medical research institute. PATIENTS: Ninety non-treatment-seeking alcohol-dependent (by DSM-IV criteria) and 17 social drinking (< 14 drinks per week) paid volunteers recruited through advertisements at an academic center. INTERVENTIONS: A taste of alcohol and a series of alcohol-related pictures, neutral beverage pictures, and visual control images were provided to volunteers after 7 days of double-blind randomly assigned daily dosing with 50 mg of naltrexone (n = 23), 0.50 mg of ondansetron hydrochloride (n = 23), the combination of the 2 medications (n = 20), or matching placebos (n = 24). MAIN OUTCOME MEASURES: Difference in brain blood oxygen level-dependent magnetic resonance when viewing alcohol pictures vs neutral beverage pictures with a particular focus on ventral striatum activity comparison across medication groups. Self-ratings of alcohol craving. RESULTS: The combination treatment decreased craving for alcohol. Naltrexone with (P = .02) or without (P = .049) ondansetron decreased alcohol cue-induced activation of the ventral striatum. Ondansetron by itself was similar to naltrexone and the combination in the overall analysis but intermediate in a region-specific analysis. CONCLUSIONS: Consistent with animal data that suggest that both naltrexone and ondansetron reduce alcohol-stimulated dopamine output in the ventral striatum, the current study found evidence that these medications, alone or in combination, could decrease alcohol cue-induced activation of the ventral striatum, consistent with their putative treatment efficacy.
Authors: Roberto I Melendez; Zachary A Rodd-Henricks; Eric A Engleman; Ting-Kai Li; William J McBride; James M Murphy Journal: Alcohol Clin Exp Res Date: 2002-03 Impact factor: 3.455
Authors: David A Kareken; Merav Sabri; Alexander J Radnovich; Eric Claus; Brian Foresman; Dwight Hector; Gary D Hutchins Journal: Neuroimage Date: 2004-05 Impact factor: 6.556
Authors: B E Wexler; C H Gottschalk; R K Fulbright; I Prohovnik; C M Lacadie; B J Rounsaville; J C Gore Journal: Am J Psychiatry Date: 2001-01 Impact factor: 18.112
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Joseph P Schacht; Patrick K Randall; Patricia K Latham; Konstantin E Voronin; Sarah W Book; Hugh Myrick; Raymond F Anton Journal: Neuropsychopharmacology Date: 2017-04-14 Impact factor: 7.853
Authors: Joseph P Schacht; Raymond F Anton; Konstantin E Voronin; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick Journal: Neuropsychopharmacology Date: 2012-10-03 Impact factor: 7.853
Authors: Joseph P Schacht; Raymond F Anton; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick Journal: Psychopharmacology (Berl) Date: 2013-02-07 Impact factor: 4.530
Authors: Claire E Wilcox; Eric D Claus; Sara K Blaine; Marilee Morgan; Kent E Hutchison Journal: J Stud Alcohol Drugs Date: 2013-03 Impact factor: 2.582
Authors: David A Kareken; Veronique Bragulat; Mario Dzemidzic; Cari Cox; Thomas Talavage; Dena Davidson; Sean J O'Connor Journal: Neuroimage Date: 2010-01-08 Impact factor: 6.556
Authors: William J A Eiler; Mario Dzemidzic; K Rose Case; Robert V Considine; David A Kareken Journal: Chemosens Percept Date: 2012-03-01 Impact factor: 1.833
Authors: James J Prisciandaro; Hugh Myrick; Scott Henderson; Aimee L McRae-Clark; Elizabeth J Santa Ana; Michael E Saladin; Kathleen T Brady Journal: Drug Alcohol Depend Date: 2013-03-14 Impact factor: 4.492